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The potential use of drugs to enhance cognition, emotion, and executive function has engendered contro-
versy despite the fact that few such agents exist today. Here, I provide a context for discussions based on
medical, regulatory, and ethical concerns that have been raised by the possibility that enhancers will emerge
from current efforts to discover drugs for neuropsychiatric disorders.To prosper and flourish in a rapidly
changing world, we must make the
most of all our resources—both
mental and material. Globalization
and its associated demands for
competitiveness are increasing
the pressures in our working lives.
Added to this are the demands
from evolving family structures
and increased care responsibilities,
both for children and for older rela-
tives. (Beddington et al., 2008)
What exactly is it about ‘‘man’s
estate’’ that most calls for relief?
Just sickness and suffering, or
also such things as nastiness, folly,
and despair? Must ‘‘improvement’’
be limited to eliminating these and
other evils, or should it also encom-
pass augmenting our share of posi-
tive goods—beauty, strength,
memory, intelligence, longevity, or
happiness itself?.even assuming
that we could agree on which
aspects of the human condition
call for improvement, we would still
face difficulties deciding how to
judge whether our attempts at
improving them really made things
better—both for the individuals
and for the society. (President’s
Council on Bioethics, 2003)
The controversy swirling around
possible—and indeed current—uses of
biotechnology (drugs, stem cells, brain-
machine interfaces) to enhance human
cognition, emotion, and executive func-
tion is illustrated by contrasting two
government sponsored reports, one
from the UK and one from the US. (Neither
of the sponsoring administrations are still
in office). Beddington et al. (2008), inannouncing the Foresight Mental Capital
and Wellbeing Project (Government
Science Office, 2008), call directly for
efforts to boost what they call mental
capital, i.e., cognitive abilities and
emotional and behavioral regulation. The
report does not make a direct recommen-
dation for technological approaches to
enhancement, focusing instead on
prevention and early intervention in condi-
tions that impair mental capital formation
and well-being. A fair reading, however,
could find the implication that enhance-
ment strategies could play a role as part
of an integrated strategy to improve
productivity and well-being in an increas-
ingly competitive and unforgiving world.
In contrast, the President’s Council on
Bioethics (2003) chaired by Leon Kass
worried that the very attractiveness of
technologies to enhance performance
and well-being in an increasingly compet-
itive world, might lead individuals and
societies to lose sight of the significant
hidden costs of such interventions. In the
Council’s view the potential costs are
many, including acceptance of short-cuts
(much like anabolic steroid use in sports)
that undermine the intrinsic value of toil
and self-improvement, and ultimately the
instrumentalization of human beings as
performancemachines. It should be noted
that performance enhancement in school
or at work has significant differences, as
well as similarities, to the situation in
sports. In most organized sports, there
are rules and sanctions grounded in the
notion that sports fans pay to see the
results of talent and training rather than
the cleverness of one’s pharmacist. In
most other areas of life, however, there
are no such rules beyond the basic laws
that require prescriptions for some drugs
and rule others illegal.Neuron 69,In school and the workplace, perfor-
mance enhancement can be quite
seductive. Faced with limited places in
prestigious schools or the high-stakes
multitasking of modern work life, who
would not consider a few extra cups of
coffee during the day to enhance alert-
ness and cognitive performance? As an
ever-greater premium is placed on
performance whether in school or in the
workplace, prescription stimulants (albeit
not always legally prescribed) such as
modafinil, methylphenidate, and am-
phetamine derivatives are increasingly
supplementing caffeine-containing bev-
erages (Sahakian and Morein-Zamir,
2007). Militaries have long employed
stimulants, including amphetamines, to
increase alertness and performance in
the face of fatigue (Caldwell and Cald-
well, 2005; Moreno, 2006).
The Treatment-Enhancement
Distinction
Extensive (and generally unenlightening)
discussions have been dedicated to
definitions and distinctions among pre-
vention, treatment, and enhancement—
unenlightening because, for the hard
cases that policy makers may face when
issuing practice guidelines or deciding
what insurance should pay for, the distinc-
tions often prove quite slippery. Given
the brevity of this essay, I will therefore
eschew definitions in favor of an example.
Based on studies of safety and efficacy,
prescription of statin drugs (inhibitors of
HMG-CoA reductase, the rate limiting
enzyme in cholesterol biosynthesis) is no
longer limited to individuals with the very
highest levels of LDL cholesterol. Indeed
prescription of these drugs has been
broadly extended to healthy people
whose cardiovascular risk would, notFebruary 24, 2011 ª2011 Elsevier Inc. 595
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able. Statin drugs substantially improve
blood lipid profiles in almost all people
and decrease LDL cholesterol to levels
that could not generally be achieved or
realistically sustained by diet and exer-
cise. Some grumpy public health figures
may harbor grievances about the moral
hazards of statins: for example, some
slovenly individuals may feel entitled to
an extra portion of dessert. Among most
physicians and policy makers, however,
there is appropriately very little hand
wringing about statin use. Here is the defi-
nitional slipperiness: instead of saying
that statins are used as enhancements
that make people who have always been
considered healthy ‘‘better than well’’
(extending longevity beyond what can be
achieved without biotechnology), medi-
cine altered the criteria for desirable LDL
cholesterol levels so that statins can be
used as bona fide treatments for a risk
state (and thus, inter alia, their use can
be covered by many insurance policies).
In the case of cognition, emotion,
and behavior, the boundary is heavily
contested between enhancement and
disorders that warrant treatment. This
contestation reflects, in part, the lack of
scientifically convincing demarcations
between illness and such conditions of
life as ‘‘normal’’ reactions to disappoint-
ments, losses, stress, and the like or
having been born with a currently disfa-
vored temperament, such as significant
shyness. The Diagnostic and Statistical
Manual of Mental Disorders, 4th edition,
Text Revision (DSM-IVTR, American
Psychiatric Association, 2000) defines
illnesses categorically (i.e., as entities
discontinuous from each other and from
normalcy, like pancreatic cancer or tuber-
culoses), not quantitatively or dimension-
ally (like hypertension or type II diabetes
mellitus). As such, it stipulates precise
thresholds for illness; thus major depres-
sion is diagnosed when a person has at
least 5 of 9 listed symptoms for at least
2 weeks. In fact, these thresholds do not
withstandmuch scientific scrutiny. A large
and growing literature finds that most
common neuropsychiatric disorders,
including depression, attention deficit
hyperactivity disorder (ADHD), and autism
are actually better understood dimension-
ally with no bright line (or ‘‘point of rarity’’)
between illness and health (Hyman,596 Neuron 69, February 24, 2011 ª2011 Els2010). This is not surprising for common
disorders in which risk is heavily influ-
enced by a very large number of common
genetic variants of small effect (although
autism can also result from highly pene-
trant mutations or copy number variants).
Disease definitions, most significantly
definitions of dimensional disorders, are
comprised of a scientific component that
stipulates the characteristic pathology,
disordered function, or risk state, and
a policy component that sets thresholds
for diagnosis and for intervention. As
noted, treatment thresholds for LDL
cholesterol level have been changed in
recent years—as have thresholds for
diagnosis and treatment of hypertension.
Having elaborated on some of the
reasons for the fuzziness of the line
separating enhancement from treatment,
I would propose a thought experiment.
ADHD is characterized by abnormal
attention, impulsivity, and hyperactivity.
Children with ADHD tend to underperform
their potential in school, to be extruded
fromprosocial peer networks, to generally
annoy adults, and, when untreated, have
an elevated risk of substance-use disor-
ders. Many clinical trials using DSM-III,
and later DSM-IV, diagnostic criteria
have found stimulant drugs to be safe
and effective at reducing the symptoms
of ADHD, with the caveat, based on
naturalistic follow-up, that most children
do not receive optimal dosing. In the
‘‘real world,’’ there are marked variations
in recognition of ADHD and stimulant
treatment by region and by country.
Many children who are treated with stimu-
lants and appear to benefit do not actually
meet DSM-IV criteria (Angold et al., 2000).
Now, if we were to take seriously the
Foresight Mental Capital and Wellbeing
Project (Government Science Office,
2008) and recognize that ADHD (pace
DSM-IV) differs from health only quantita-
tively on dimensions that measure atten-
tion, impulse control, andmotoric activity,
should we not consider lowering the diag-
nostic thresholds so that more children
could be treated? In contrast to altering
standards for cholesterol and blood pres-
sure, I would predict that such a sugges-
tion would create an uproar, only a small
fraction of which would be based on
issues of safety, efficacy, and cost. At
a minimum one could conclude that
controversies over enhancement of neu-evier Inc.ropsychological function, especially in
children, are treated very differently from
interventions that influence organs other
than the brain.
Safety and Efficacy
While less philosophically engaging than
other aspects of the enhancement
controversy, I would argue that questions
of safety deserve serious attention.
Unless surprising changes occur in global
regulatory frameworks, all new drugs will
continue to be developed and marketed
for specific disease indications rather
than to make healthy people better than
well. Some drugs, such as lithium or
most antimicrobials, only have thera-
peutic effects in the presence of certain
disease states. For a drug to act as an
enhancer, it must have a mechanism
that permits its beneficial actions to occur
in the absence of illness. Drugs such as
the already discussed statins and stimu-
lants have mechanisms that fulfill this
latter criterion. (There is some evidence,
however, that stimulants exert the great-
est benefit on executive function for indi-
viduals who are initially impaired). Given
current rules governing approvals, drugs
come to be used for enhancement only
after they are approved to treat an illness.
Subsequently they are obtained through
physicians prescribing ‘‘off label’’ or by
diversion from other patients. I have no
doubt that once drugs are approved that
can also act as enhancers, people will
find inventive, and not always legal,
ways to obtain them.
The effects of stimulants taken for
enhancement do not differ markedly
from their effects for approved indications
(ADHD and disorders of excessive sleep-
iness): Stimulants increase arousal,
improve attention, increase motivation,
and improve aspects of learning and
memory. Other drugs being sought for
several other disease indications may
eventually prove to have properties that
would permit their use as enhancers.
These include several different mecha-
nisms being investigated for the symp-
tomatic improvement of memory in Alz-
heimer’s disease as well as drugs (that
might be similar or identical) to enhance
extinction learning in anxiety disorders.
The currently available antidepressants
have only modest positive effects in
healthy people, (and only moderate
Neuron
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but ultimately antidepressant drugs might
be developed that safely elevate mood
not only in depressed but also in dis-
tressed or pessimistic people who are
healthy. Another interesting possibility
might come from drugs to treat social
deficits in autism spectrum disorders.
Extrapolating from studies with the
hormone oxytocin in healthy volunteers,
it is imaginable that drugs targeted to
social cognition could enhance trust or
feelings of interpersonal closeness.
Another, perhaps farther off, possibility
includes drugs to disrupt memory recon-
solidation. In combination with carefully
selected stimuli to call up the memories
to be targeted, such drugs would be
used to wipe out traumatic memories in
posttraumatic stress disorder or drug
cues that propel relapses in addiction.
(Extinction learning leaves suchmemories
intact, but suppresses them, leaving a risk
of relapse.) Drugs that disrupt memory
reconsolidation would have significant
safety hurdles to pass—there would be
a significant risk of wiping out important
adaptive memories—but if approved,
one could imagine (and worry about) ‘‘off
label’’ attempts to remove unpleasant
memories that detracted from a person’s
happiness or self-esteem. In a nightmare
scenario, such drugs might be misused
by criminal perpetrators to overwrite
unwanted intrusions of misdeeds and
thus, perhaps conscience—such a drug
is what Shakespeare has Lady Macbeth
asking for. In the context of suchmusings,
it is important to recall just how difficult
it has been to develop such drugs
with the unimpeachable goal of treating
serious illnesses, including treatment
refractory depression, posttraumatic
stress disorder, addiction, and demen-
tias. If problems arise with respect to
use of such agents for enhancement, it
will mean that we finally possess much
needed treatments for neuropsychiatric
disorders, treatments that have long
remained stubbornly out of reach.
Of course, all drugs and technologies
have risks. For regulators and from
a public health point of view, an accept-
able ratio of risk to benefit is far different
when people have a life-threatening
illness as opposed to when they have
milder symptoms or when they are well
to begin with. For example, drugs withthe severe side effect profiles of cytotoxic
cancer chemotherapies would not be
approved for mild disorders like allergic
rhinitis. Greely et al. (2008) have called
for a program of research on cognitive
enhancers in healthy individuals. To
date, studies of stimulants in healthy
people have been limited largely to
single-dose laboratory experiments;
longer-term clinical trials to investigate
whether there is significant and lasting
efficacy for cognitive enhancement have
not been performed. The problem with
conducting such trials is precisely the
risk of producing any serious harm in
people with no illness. Stimulant drugs
have some cardiovascular risks, and the
amphetamine derivatives, and possibly
methylphenidate, pose real risks of addic-
tion. The libertarian in me suggests that
informed consent should remove a major
obstacle to clinical trials. The realist in
me wonders who might then accept the
responsibility, if not the liability, for
producing and marketing them. The
public health-oriented physician in me
sadly recognizes that clinical trials data
often fail to inform practice and that in
any case most psychotropic drugs
perforce are prescribed by generalist
physicians with little training about their
effects or side effects and little time to
monitor for dosage escalation.
Fairness and Implicit Coercion
Health insurance is highly unlikely to pay
for enhancements. Thus a concern often
raised about making drugs available to
enhance cognition, emotion, and execu-
tive function is the possibility of increasing
the ‘‘opportunity gap’’ between the rich
and educated (who are more likely to
request antidepressants and stimulants
as treatments) and the poor and less
educated. It is possible that chemical
‘‘haves,’’ whose children already have
the benefit of lessons and tutors, better
health care, and better nutrition, will gain
for their offspring an even greater educa-
tional advantage than the children of the
chemical ‘‘have-nots.’’ The substantial,
and by many indices growing, economic
and educational gaps between rich and
poor are not likely to be conducive to the
long-term flourishing of our society. While
the enhancement issue should not be
glibly declared irrelevant, it is hard to
imagine that the problem of disparities,Neuron 69,which already plague US health care
and public education will be worsened
materially based on the question of who
will request and who can pay for
enhancing drugs. A more fruitful first
step for decreasing disparities in health
care and education would be to improve
the recognition and treatment of im-
pairing mental illnesses among the
disadvantaged.
Another concern about enhancement is
that of implicit coercion and thus the risk
of an arms race. I am no expert on the
current state of performance enhance-
ment in sports, but an arms race problem
can be at least hypothetically illustrated
by the predicament of a fictional interior
lineman playing US football in a time or
place with little effective antidoping
enforcement. A player who did not want
to take anabolic steroids or growth
hormone when nearly everyone else,
including his own teammates, was taking
such drugs, would be at a significant
disadvantage, ‘‘playing naked’’ as it has
been said. If an athletic scholarship or
a high salary were at stake, it might be
very difficult to resist the unfortunate
community norm. This scenario can be
extended to performance enhancement
with psychotropic drugs. Given that the
rates of stimulant prescription tend to be
highest in affluent schools (and in some
documented cases well above the preva-
lence of DSM-IV ADHD), it is reasonable
to surmise that some parents have
already entered their progeny in apharma-
cologic performance arms race. One
wonders whether students will one day
have to provide a urine sample before
taking a high stakes exam if truly effective
memory enhancing drugs are ever devel-
oped and marketed.
Further Considerations
In my view, a serious problem for science
is the dearth of truly efficacious new drugs
to treat neuropsychiatric disorders. It
would be a terrible error to impede prog-
ress in drug discovery and development
(as some critics of biotechnology have
suggested) in order to avoid managing
their possible use as enhancements (Fu-
kuyama, 2002). Aside from concerns
about safety, social justice, and implicit
coercion, discussed above, other difficult,
unresolved issues arise that justify fuller
discussion than is possible here.February 24, 2011 ª2011 Elsevier Inc. 597
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really do not know how useful stimulants
are in regular use for enhancement.
Some worry that the prescription of these
drugs to children ingrains in them malign
lessons about taking short-cuts, elevating
performance over other values, or
believing that learning or self-control
come from a pill bottle. The evidence for
this dark view is lacking (Singh, 2008).
The question is often raised about
the possibility of terrible, still unknown,
long-term side effects of stimulants—we
do know about appetite suppression,
growth delay, and insomnia. One should
not be cavalier, but these drugs have
been in use for decades, and long-term
cohorts have been followed for a variety
of reasons, making it unlikely that we
are missing some truly awful long-term
side effect. The lack of solid empirical
knowledge on all these points opens the
arena for noisy disagreements (Singh,
2008).
From a policy point of view, however,
I do not think that societies have been
really tested yet. The existing cognitive
enhancers are simply not so potent as to
tilt the scales of advantage overmuch. If
truly safe and effective memory enhance-
ment becomes possible, I believe that it
will be incumbent on society to develop
the right regulatory regime. It is difficult
to predict whether that regime will be
one of restriction, or, imagining years of
experience that demonstrates the possi-
bility of safe transient use in discrete
settings (e.g., not when there is risk
of injury or danger), a regime of wider
distribution. Wide distribution of truly598 Neuron 69, February 24, 2011 ª2011 Elseffective cognitive enhancers will make
our world different in unpredictable ways
that are well worth discussing ahead
of time.
Perhaps the most concerning drugs to
me are those that alter what are called
moral emotions such as trust. Drug for
memory erasure fall into this category
because they could be used to obliterate
selected life lessons, including moral
lessons, connected as they most often
are to shame and guilt. Such drugs, if truly
effective could lead to manipulation of
others and highly problematic even
dangerous individual behavior.
In a free society people, including the
kinds of people who read this journal,
have always found ways to experiment
with drugs, legal or not, in order to banish
pain, distress, fatigue, and a sense of limi-
tation (Sahakian and Morein-Zamir,
2007). Arguments that people must
passively accept their draw in the
genetic-developmental lottery, if safe
and effective enhancements are possible,
can be seen as paternalistic if not cynical.
People have always sought advantage for
themselves and their family and friends,
which is why our economic system
(some large recent hiccups notwith-
standing) has been so successful. In
short, I believe that if drugs discovered
and developed for medical purposes
also increase self-mastery, provide
a competitive edge, or increase happi-
ness (or decrease unhappiness) in healthy
people, they will find such uses. Despite
the frustrating difficulty of developing
new generations of drugs to treat neuro-
psychiatric disorders for which there isevier Inc.a powerful medical need, it is not too early
to begin to think about the kind of
research, education, and enlightened
regulation that we will need should such
drugs turn out to function also as
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